Quantitative Concept – Page 52

FDA Approves Pfizer’s Hemophilia B Gene Therapy with a $3.5 Million Price Tag

2 years ago talkbio0Tagged Approved, Biotechnology, Financial cost, gene therapy, Health care facility, Hemophilia B, Hereditary Diseases, Pfizer, Pricing, United States Food and Drug Administration

Pfizer, FDA, hemophilia B, gene therapy, approval, pricing, healthcare, biotechnology, rare diseases, genetic disorders, treatment cost.

Merck & Co.’s Q1 Success Driven by Keytruda, Ups 2024 Outlook

2 years ago talkbio0Tagged Cancer Therapeutic Procedure, Co., earnings, Keytruda, Projections and Predictions

Merck & Co., Q1 earnings, Keytruda, pharmaceuticals, cancer treatment, 2024 forecast

Lilly Acquires Injectable Medicines Production Facility from Nexus Pharma

2 years ago talkbio0Tagged Acquisition (action), Capacity, Eli Lilly, expansion, Facility (object), Injectables, Nexus Pharma, pharmaceutical manufacturing, production, strategic

Lilly, Nexus Pharma, injectable medicines, facility acquisition, pharmaceutical manufacturing, strategic expansion, production capacity.

Senator Sanders Investigates Skyrocketing Costs of Novo Nordisk’s Diabetes and Weight Loss Drugs

2 years ago talkbio0Tagged Affordability, Diabetes, Evaluation, Health care facility, Nordisk, Novos, Prices, Senator Bernie Sanders, Wegovy

Senator Bernie Sanders, Novo Nordisk, diabetes, weight loss, drug prices, Novos Ozempic, Wegovy, investigation, healthcare costs, affordability

Eli Lilly Expands Manufacturing Capacity with Nexus Plant Acquisition Amid Ongoing Mounjaro and Zepbound Supply Challenges

2 years ago talkbio0Tagged Acquisition (action), Capacity, Drug Industry, Drug shortages, Eli, Eli Lilly, Manufacture, Mounjaro, Nexus manufacturing, Plants, Wisconsin, Zepbound

Eli Lilly, Nexus manufacturing plant, Wisconsin, Mounjaro, Zepbound, drug shortages, manufacturing capacity, pharmaceutical industry, acquisition

BMS Expands CAR-T Therapy Capabilities with Strategic $380 Million Investment in Cellares

2 years ago talkbio0Tagged Automation, Biotechnology, Burning Mouth Syndrome, Cancer Therapeutic Procedure, Capacity, CAR-T, Cell Therapy, Cellares, expansion, Investments, Manufacture, squibb

BMS, Bristol Myers Squibb, Cellares, CAR-T therapy, cell therapy, cancer treatment, biotechnology, investment, capacity expansion, manufacturing, automation.

CSL Vifor’s Corrective Marketing Initiative to Address Anti-Competitive Concerns

2 years ago talkbio0Tagged anti-competitive practices, competition, Corrective, CSHL1 gene, Drug Industry, fairness, Market, Measures, Vifor

CSL Vifor, marketing campaign, anti-competitive practices, competition law, corrective measures, pharmaceutical industry, competition watchdog, market fairness.

Sanofi Restructures US Commercial Vaccine Group Amid Cost-Saving Campaign

2 years ago talkbio0Tagged Commercial Vaccine, Cost-Savings Campaign, Effectiveness, Efficiency, Employee, Evolving, Market, Optimization, Outplacement, restructuring, sanofi, streamlined strategic sales, Structure, Vaccines

Sanofi, Restructuring, US Commercial Vaccine Group, Cost-Savings Campaign, Streamlined Strategic Sales Structure, Evolving Vaccine Market, Optimization for Efficiency and Effectiveness, Employee Support and Outplacement Assistance

CMS to Increase Reimbursement for New Sickle Cell Gene Therapies through Outcomes-Based Agreements

2 years ago talkbio0Tagged Administrative action, Burden, Casgevy, Cells, Centers for Medicaid and Medicare (CMS) Pnl, Central, CGT, Equitable Access, Fertility, Grail, Increased, Lyfgenia, Medicaid Access, Medicare & Medicaid Services, OBAs, Outcomes-Based Agreements, Reimbursement, sickle cell gene therapies

CMS (Centers for Medicare & Medicaid Services), Sickle Cell Gene Therapies, Increased Reimbursement, Outcomes-Based Agreements (OBAs), Cell and Gene Therapy (CGT) Access Model, Medicaid Access, Casgevy, Lyfgenia, Fertility Preservation Services, Equitable Access, Administrative Burden Reduction

Intra-Cellular’s Caplyta Triumphs in Major Depressive Disorder Phase 3 Trial, Edging Closer to FDA Filing

2 years ago talkbio0Tagged Caplyta, CGI-S, Clinical Global Impression Original Version Questionnaire, clinically, File (record), Intra-Cellular Therapies, Lumateperone, MADRS, MDD, Montgomery-Åsberg depression rating scale, Phase 3 trial, Positive, results, Severities, Statistical Significance, Unipolar Depression, United States Food and Drug Administration

Intra-Cellular Therapies, Caplyta, Lumateperone, Major Depressive Disorder (MDD), Phase 3 Trial, Positive Results, Statistically Significant, Clinically Meaningful, Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression Scale for Severity of Illness (CGI-S), FDA Filing